Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Evonik invests in pain relief implant developer Allay

by Rick Mullin
December 15, 2022 | A version of this story appeared in Volume 100, Issue 44

 

An image of the inside of a knee.
Credit: Evonik Industries
Allay Therapeutics' knee implant uses biodegradable polymers from Evonik Industries.

Evonik Industries has invested in Allay Therapeutics, which is developing an implant for treating pain after knee surgery. The technology, according to Evonik, may allow patients to forgo opioid painkillers such as morphine and oxycodone. The German chemical company makes biodegradable polymers used in the coin-sized implant to ensure that the active ingredient is delivered in a controlled fashion over a long period. Allay says it has succeeded in sustaining delivery for as long as 3 weeks.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.